Cargando…
索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808861/ https://www.ncbi.nlm.nih.gov/pubmed/36709189 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.11.013 |
| _version_ | 1784863016646344704 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9808861 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Editorial office of Chinese Journal of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98088612023-01-09 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析 Zhonghua Xue Ye Xue Za Zhi 经验交流 Editorial office of Chinese Journal of Hematology 2022-11 /pmc/articles/PMC9808861/ /pubmed/36709189 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.11.013 Text en 2022年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License. |
| spellingShingle | 经验交流 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析 |
| title | 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析 |
| title_full | 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析 |
| title_fullStr | 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析 |
| title_full_unstemmed | 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析 |
| title_short | 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析 |
| title_sort | 索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗flt3-itd突变阳性急性髓系白血病12例的疗效及安全性分析 |
| topic | 经验交流 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808861/ https://www.ncbi.nlm.nih.gov/pubmed/36709189 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.11.013 |
| work_keys_str_mv | AT suǒlāfēiníliánhéwéinàikèlāāzhābāogānfāngànyòudǎozhìliáoflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìng12lìdeliáoxiàojíānquánxìngfēnxī AT suǒlāfēiníliánhéwéinàikèlāāzhābāogānfāngànyòudǎozhìliáoflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìng12lìdeliáoxiàojíānquánxìngfēnxī AT suǒlāfēiníliánhéwéinàikèlāāzhābāogānfāngànyòudǎozhìliáoflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìng12lìdeliáoxiàojíānquánxìngfēnxī AT suǒlāfēiníliánhéwéinàikèlāāzhābāogānfāngànyòudǎozhìliáoflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìng12lìdeliáoxiàojíānquánxìngfēnxī AT suǒlāfēiníliánhéwéinàikèlāāzhābāogānfāngànyòudǎozhìliáoflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìng12lìdeliáoxiàojíānquánxìngfēnxī AT suǒlāfēiníliánhéwéinàikèlāāzhābāogānfāngànyòudǎozhìliáoflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìng12lìdeliáoxiàojíānquánxìngfēnxī AT suǒlāfēiníliánhéwéinàikèlāāzhābāogānfāngànyòudǎozhìliáoflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìng12lìdeliáoxiàojíānquánxìngfēnxī |